In the realm of investing, nano-cap OTC stocks often present opportunities for potential price swings. Investors are consistently on the lookout for catalysts that could impact these price movements, and one notable driver is often news. Positive news releases have the potential to significantly boost stock prices.
Let’s take a look at four OTC nano-cap stocks that have recently made moves that are gaining investor attention:
Sekur Private Data Ltd. (OTCQX:SWISF) (CSE:SKUR)
SWISF is a prominent player in the cybersecurity sector, specializing in secure and confidential online communications. In a significant announcement dated October 3, 2023, Sekur unveiled strategic initiatives that signaled a pivotal moment for the company.
The core of this strategic initiative involves the company’s expansion into the DACH region, encompassing Germany, Austria, and Switzerland. This expansion is rooted in the launch of Sekur, its Swiss-hosted communications suite, in the German language. A targeted digital marketing campaign will be launched in the DACH region in conjunction with the release of Sekur in German, set to be in full swing by the end of Q4 2023, according to the press release.
SWISF emphasized the substantial economic influence that the DACH region holds, boasting a combined GDP of approximately 5.35 trillion U.S. dollars. Additionally, Germany’s economy is the largest in Europe, with the majority of the country’s GDP coming from its service sector. The country’s service sector encompasses tourism, financial services, real estate, and other industries. This reflects Germany’s standing as a central financial and political pillar of the European Union and its position as a popular tourist destination. These strong economic foundations suggest promising opportunities for Sekur’s services.
Recent accounts of cyberattacks targeting German websites, including a significant IT provider, Bitmarck, have highlighted the urgency for effective cybersecurity solutions in the DACH region. Sekur has already witnessed a surge in interest from Germany, ranking among the top five countries in searches for its services. Notably, customers in Germany are conducting transactions in the local Euro currency, signifying a substantial demand for Sekur’s solutions, according to SWISF.
By offering its services in the German language and extending its presence into the DACH region, Sekur aims to tap into a vast market encompassing over 100 million people. This strategic expansion aligns seamlessly with the company’s mission to provide private and secure communications to a broader audience.
Alain Ghiai, CEO of Sekur Private Data, expressed enthusiasm about the company’s expansion plans. He noted the escalating need for cybersecurity solutions in Germany, particularly in the face of a rising number of cyberattacks. Ghiai emphasized that offering services in the German language opens doors to an untapped market.
SWISF’s move into the DACH region, coupled with the region’s economic prominence and cybersecurity challenges, presents compelling opportunities. Investors interested in the cybersecurity sector will undoubtedly monitor Sekur Private Data Ltd. closely for its potential impact in this dynamic industry.
Epazz Inc. (OTC:EPAZ)
EPAZ has been making waves recently in the world of drone technology with its subsidiary, ZenaDrone. In a press release dated October 3, 2023, Epazz announced a significant milestone: the deployment of the first drones manufactured at ZenaDrone’s new facility in Ireland. This move marks the beginning of Drone as a Service (DaaS) operations in the country, and it’s already generating excitement in the world of penny stocks.
What’s truly remarkable about this development is the potential for substantial revenue generation. Epazz estimates that each deployed drone can bring in over $100,000 per year. But let’s dive deeper into what this means for investors and why it’s worth keeping an eye on EPAZ.
According to the press release, ZenaDrone will collaborate with Irish farmers to monitor plant health and provide weed control. Moreover, the drones will play a crucial role in supporting local police and fire departments as an integrated part of their first-responder systems. This multifaceted approach showcases the versatility and real-world utility of ZenaDrone’s technology.
This announcement follows a string of recent victories for EPAZ, including the growing interest in ZenaDrone within the United States military. High-ranking personnel from the United States Navy have chosen the ZenaDrone 1000 for a significant presentation, scheduled for the near future. This kind of recognition within the defense sector speaks volumes about the capabilities of ZenaDrone’s technology.
Furthermore, Epazz has been taking strategic steps to expand its presence globally. With the establishment of a base in Germany, the company is positioning itself to tap into the thriving European drone market. This move aligns with its goal of becoming a major player in the European drone industry.
EPAZ also recently announced that they entered into a strategic partnership with Thunder Tiger, a well-known Taiwanese defense contractor, better positioning EPAZ for contracts with the U.S. government away from restricted Chinese manufacturers. “Taiwan has resolved our supply chain issues, allowing us to become NDAA compliant so we can show the U.S. Defense Department the ZenaDrone 1000 “Taiwan has resolved our supply chain issues, allowing us to become NDAA compliant so we can show the U.S. Defense Department the ZenaDrone 1000 capabilities,” said Shaun Passley, Ph.D., CEO of Epazz and ZenaDrone. “We believe that our advanced drone technology can help to improve the efficiency of supply chain operations and create new opportunities for both sides.”
In summary, Epazz Inc.’s recent press release regarding ZenaDrone’s deployment in Ireland signifies a pivotal moment for the company. The potential for substantial revenue generation, coupled with recognition from the United States Navy and strategic global expansion, means EPAZ could be a worthy stock for any savvy investor’s watchlist.
Odyssey Health Inc. (OTCQB:ODYY)
Odyssey Health Inc. is a medical company with a strong focus on life-enhancing medical solutions. Their mission is to create, acquire, and develop exceptional technologies and assets that provide meaningful medical advancements. Recently, on October 4, 2023, the company made a significant move by up-listing to the OTCQB market from the OTC Pink market. This development marks a crucial milestone for Odyssey Health, expanding its investor base and driving enhanced clinical efficacy.
The company’s Chairman and Chief Executive Officer, Michael Redmond, expressed their commitment to advancing unique nasal delivery solutions for proprietary compounds aimed at treating neurological disorders, including mild traumatic brain injury (mTBI), commonly known as concussion. This demonstrates Odyssey Health’s dedication to delivering valuable medical solutions and creating shareholder value.
In a recent press release on October 5, 2023, it was announced that Oragenics, Inc. (NYSE American:OGEN) and Odyssey Health have signed a definitive agreement. Under this agreement, Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies. This includes drug candidates for treating mTBI and Niemann-Pick Disease Type C (NPC), as well as Odyssey’s proprietary powder formulation and nasal delivery device.
The strategic acquisition involves cash payments totaling $1.0 million and eight million shares of Oragenics Series F Convertible Preferred Stock. The transaction is expected to close in the fourth quarter of 2023, subject to various closing conditions, including shareholder approvals.
Odyssey Health’s lead concussion asset, ONP-002, is a promising intranasal drug candidate for treating moderate-to-severe concussion. It has shown positive results in preclinical studies, demonstrating rapid brain biodistribution, reduced swelling and inflammation, and an excellent safety profile. ONP-002 has completed Phase 1 clinical trials and is set for Phase 2 trials to further evaluate its safety and efficacy.
This strategic collaboration positions Oragenics to harness expertise in intranasal administration, potentially addressing a critical need for concussion treatment in a market where there is currently no FDA-approved solution. Odyssey Health’s commitment to neurological drug candidates and their partnership with Oragenics highlight their dedication to advancing healthcare solutions.
Argentina Lithium & Energy Corp. (OTC:PNXLF) (TSXV:LIT)
Argentina Lithium & Energy Corp. is a company focused on acquiring high-quality lithium projects in Argentina to meet the increasing global demand from the battery sector. Their team, with a strong history of success in Argentina’s resource sector, is dedicated to advancing the best lithium properties in the renowned “Lithium Triangle.”
On October 5, 2023, the company announced the successful closing of a substantial US$90 million investment in Argentina Litio y Energia S.A. (ALE) by Stellantis, a world-renowned automaker and mobility provider with iconic brands such as Abarth, Alfa Romeo, Fiat, Jeep, and more. In this transaction, Peugeot Citroen Argentina S.A., a Stellantis subsidiary, invested the ARS equivalent of US$90 million to acquire ALE shares, marking a significant partnership.
As part of this deal, Argentina Lithium granted Stellantis an “Exchange Right” to potentially exchange ALE shares for up to 19.9% of Argentina Lithium’s outstanding common shares in the future, subject to specific conditions outlined in an exchange agreement. The parties have also entered into a lithium offtake agreement, a shareholders’ agreement concerning ALE, and, upon exercising the exchange right, an investor rights agreement.
With this transaction, Stellantis now holds 19.9% of ALE shares, while Argentina Lithium retains 80.1% ownership. The proceeds from this investment will be instrumental in advancing Argentina Lithium’s lithium projects in Argentina and for general corporate purposes.
Stellantis, a leader in the automotive industry, joins forces with Argentina Lithium, signifying a strategic move towards sustainable mobility and growth in the lithium sector.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance that are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Sekur Private Data Ltd. to assist in the production and distribution of content related to SWISF. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.